hackint0sh/New-Dataset huggingface dataset:
This study seeks to develop a liquid biopsy assay that can accurately detect LNM before treatment in ICC patients. conditions: Cholangiocarcinoma conditions: Cholangiocarcinoma, Intrahepatic conditions: Cholangiocarcinoma Resectable conditions: Cholangiocarcinoma; Liver studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 200 type: ESTIMATED name: LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma) measure: Sensitivity measure: Specificity measure: Proportion of correct predictions (true positives and true negatives) among the total number of cases (i.e., accuracy) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: City of Hope Medical Center status: RECRUITING city: Duarte state: California zip: 91016 country: United States name: Ajay Goel, PhD role: CONTACT phone: 626-218-3452 email: AJGOEL@COH.ORG name: Ajay Goel, PhD role: PRINCIPAL_INVESTIGATOR name: Takayuki Noma, MD role: SUB_INVESTIGATOR lat: 34.13945 lon: -117.97729 facility: Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University status: RECRUITING city: Hokkaido state: Sapporo zip: 060-8648 country: Japan name: Akinobu Taketomi, PhD role: CONTACT email: akinobutaketomi@yahoo.co.jp name: Kazuki Wakizaka, PhD role: SUB_INVESTIGATOR name: Akinobu Taketomi, PhD role: PRINCIPAL_INVESTIGATOR lat: 43.41104 lon: 142.88878 facility: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University status: RECRUITING city: Fukuoka zip: 812-8582 country: Japan name: Masaki Mori, PhD role: CONTACT email: m_mori@surg2.med.kyushu-u.ac.jp name: Masaki Mori, PhD role: PRINCIPAL_INVESTIGATOR name: Takeo Toshima, PhD role: SUB_INVESTIGATOR lat: 33.6 lon: 130.41667 facility: Department of Surgery, Tokushima University status: RECRUITING city: Tokushima zip: 770-8503 country: Japan name: Mitsuo Shimada, PhD role: CONTACT email: mitsuo.shimada@tokushima-u.ac.jp name: Yuma Wada, PhD role: SUB_INVESTIGATOR name: Takayuki Noma, MD role: SUB_INVESTIGATOR name: Yuji Morine, PhD role: SUB_INVESTIGATOR name: Tetsuya Ikemoto, PhD role: SUB_INVESTIGATOR name: Yu Saito, PhD role: SUB_INVESTIGATOR name: Mitsuo Shimada, PhD role: PRINCIPAL_INVESTIGATOR lat: 34.06667 lon: 134.56667 hasResults: False
nctId: NCT06381635 id: FD-BUE-REC: IRB000124920 briefTitle: Effect of Aloe Vera Gel and Manuka Honey on Radiation Induced Oral Mucositis overallStatus: RECRUITING date: 2024-04-01 date: 2024-10-01 date: 2025-01-01 date: 2024-04-24 date: 2024-04-24 name: Ain Shams University class: OTHER briefSummary: The goal of this \[ type of study: Clinical trial\] is to test effectiveness of Aloe Vera Gel and Manuka Honey in management of Radiation Induced Mucositis in head and neck cancer patients.
2. Does Aloe Vera Gel and Manuka Honey affect the level of TGFβ1 and EGF in saliva of patients with radiation induced mucositis? participants will be asked to apply Aloe Vera Gel and Manuka Honey or saline three times daily during radiotherapy and 6 months after radiotherapy. conditions: Radiation Mucositis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Manuka honey mixed with aloe vera gel measure: Change from World Health Organization Oral Toxicity Scale Grading of Oral Mucositis measure: the level of salivary transforming growth factor beta 1 measure: the level of salivary Epidermal Growth factor (EGF) sex: ALL minimumAge: 20 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ain shams University status: RECRUITING city: Cairo zip: 11565 country: Egypt name: hani wlliam, MD role: CONTACT phone: +20 0001000093885 email: ethicscommittee.fdasurec@gmail.com lat: 30.06263 lon: 31.24967 facility: Fatma E.Sayed status: RECRUITING city: Cairo country: Egypt name: Fatma E. Hassanein, PHD role: CONTACT phone: +201000093885 email: fatmahassanein@dent.asu.edu.eg name: Asma Abou Bakr role: CONTACT email: Asmaa.Aboubakr@bue.edu.eg lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06381622 id: CTA no: 2023-510028-63-00 briefTitle: Combining Lidocaine and Ropivacaine for an Infraclavicular Brachial Plexus Nerve Block overallStatus: RECRUITING date: 2024-04-18 date: 2024-08-03 date: 2024-09-03 date: 2024-04-24 date: 2024-04-24 name: Nordsjaellands Hospital class: OTHER briefSummary: The aim of the study is to investigate how the combination of ropivacaine (a slow onset, long duration local anesthetic) with lidocaine (a rapid onset, shorter duration local anesthetic) affects the onset and duration of a lateral infraclavicular plexus brachialis (LIC) block in patients undergoing non-acute hand surgery. conditions: Nerve Block conditions: Anesthesia, Local conditions: Forearm Fracture conditions: Surgery conditions: Brachial Plexus Block studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 78 type: ESTIMATED name: Ropivacaine 0.5% Injectable Solution name: Lidocaine epinephrine name: Ropivacaine 0.75% Injectable Solution measure: Total time to breakthrough pain measure: The onset of sensory block measure: Total duration of sensory blockade measure: Total duration of motor blockade measure: Degree of motor blockade measure: Pain intensity at pain breakthrough measure: Duration of maximum pain intensity after the blockade has ended measure: Occurence of adverse events (AE) and serious adverse events (SAE) measure: Failed blockade measure: The patient's experience of the treatment (patient satisfaction) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nordsjælland Hospital status: RECRUITING city: Hillerød zip: 3400 country: Denmark name: Lars H Lundstrøm, PhD role: CONTACT phone: 48296512 phoneExt: 45 email: lars.hyldborg.lundstroem.02@regionh.dk name: Christian Rothe, PhD role: CONTACT phone: 48297459 phoneExt: 45 email: christian.rothe@regionh.dk lat: 55.92791 lon: 12.30081 hasResults: False
nctId: NCT06381609 id: 69HCL22_0901 briefTitle: Peer Support in Alcohol Dependence acronym: PEERSIAD overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-11-01 date: 2027-11-01 date: 2024-04-24 date: 2024-04-24 name: Hospices Civils de Lyon class: OTHER briefSummary: Alcohol use disorder (AUD) affects between 4% and 6% of French adults, and requires appropriate medical treatment.
This is the main hypothesis and the main scientific objective of the PEERSIAD study, which will aim to confirm that accompanying patients with AUD using APSSs after alcohol detoxification, reduces the rate of lost-to-follow-up and improves the overall clinical outcome. conditions: Alcohol Use Disorder studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 626 type: ESTIMATED name: Quality life questionnaire AQoLS name: Quality life questionnaire Euroqol EQ-5D-5L name: Peer support consultations measure: Unplanned cessation of care at 6 months measure: Number of unfulfilled consultations measure: Euroqol-5D-5L questionnaire score measure: Difference in costs (in euros) measure: Number of AUD criteria according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5) measure: Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) score measure: average number of standard drinks declared per week measure: Alcohol Quality of Life Scale (AQoLS) score measure: State-Trait Anxiety Inventory (STAI-Y) score measure: Montgomery-Åsberg Depression Rating Scale (MADRS) score measure: Cannabis Use Disorders Identification Test - Revised (CUDIT-R) score measure: type of opioid use measure: frequency of opioid use measure: type of psychostimulant use measure: frequency of psychostimulant use measure: Fagerström test score measure: Health Care Satisfaction Questionnaire (HCSQ) score measure: Number of hospitalisations measure: Service organization description measure: Description of type of support and missions performed by Peer Support measure: Acceptability of Intervention Measure (AIM) score measure: AIM score measure: Adoption of intervention measure: Intervention fidelity sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CH Le Vinatier city: Bron zip: 69500 country: France name: Monique GUENIN, MD-PhD role: CONTACT phone: +33 4 37 91 55 55 email: monique.guenin@ch-le-vinatier.fr name: Monique GUENIN, MD-PhD role: PRINCIPAL_INVESTIGATOR lat: 45.73333 lon: 4.91667 facility: Hôpital Beaujon city: Clichy zip: 92110 country: France name: Delphine MOISAN, MD-PhD role: CONTACT phone: +33 1 40 87 58 82 email: delphine.moisan@aphp.fr name: Delphine MOISAN, MD-PhD role: PRINCIPAL_INVESTIGATOR lat: 48.90018 lon: 2.30952 facility: GH Nord, Hospices Civils de Lyon city: Lyon zip: 69004 country: France name: Benjamin ROLLAND, Professor role: CONTACT name: Benjamin ROLLAND, Professor role: PRINCIPAL_INVESTIGATOR name: François BAILLY, MD-PhD role: SUB_INVESTIGATOR lat: 45.74848 lon: 4.84669 facility: CHS St Anne city: Paris zip: 75014 country: France name: Clément VANSTEENE, MD-PhD role: CONTACT name: Clément role: CONTACT name: VANSTEENE, MD-PhD role: PRINCIPAL_INVESTIGATOR lat: 48.85341 lon: 2.3488 facility: Bichat Hospital city: Paris zip: 75018 country: France name: Pierre-Alexis GEOFFROY, MD-PhD role: CONTACT phone: +33 1 40 25 82 60 email: pierrealexis.geoffroy@aphp.fr name: Pierre-Alexis GEOFFROY, MD-PhD role: PRINCIPAL_INVESTIGATOR lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06381596 id: 2023-1715 id: A536000 type: OTHER domain: UW- Madison id: SMPH/OPHTHAL&VIS SCI/GEN type: OTHER domain: UW- Madison id: Protocol Version 3/6/2024 type: OTHER domain: UW- Madison briefTitle: Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration acronym: FPF in AMD overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2025-04 date: 2024-04-24 date: 2024-04-24 name: University of Wisconsin, Madison class: OTHER briefSummary: The goal of this clinical trial is to learn if the areas of stressed cells in the retina correlate to areas of disease identified in standard imaging and whether the images are helpful to identify potential areas of concern before symptoms or disease occurs. The main question it aims to answer is:
Participants will undergo FPF imaging using the OcuMet Beacon system. conditions: Geographic Atrophy conditions: Age-Related Macular Degeneration studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 40 type: ESTIMATED name: OcuMet Beacon measure: Limits of agreement between the fundus autofluorescence (FAF) area of GA images taken with the Heidelberg Spectralis to the flavoprotein fluorescence (FPF) area of GA with images taken with the OcuMet Beacon measure: Compare the cross-sectional associations between FPF intensity (average pixel intensity over a 5.5 mm-diameter region centered at the macula) to FAF area at the time of measurement measure: Compare the cross-sectional associations between best corrected visual acuity (BCVA - using Early Treatment Diabetic Retinopathy Study, greater number of letters read correctly equals better vision) to FAF area at the time of measurement sex: ALL minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Ophthalmology and Visual Sciences city: Madison state: Wisconsin zip: 53705 country: United States name: Amy Remm role: CONTACT phone: 608-262-3377 email: amy.remm@wisc.edu name: Mihai Mititelu, MD, MPH role: PRINCIPAL_INVESTIGATOR lat: 43.07305 lon: -89.40123 hasResults: False
nctId: NCT06381583 id: 23228/EMERALD briefTitle: A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma acronym: EMERALD overallStatus: RECRUITING date: 2023-04-15 date: 2026-06-18 date: 2026-06-18 date: 2024-04-24 date: 2024-04-25 name: City of Hope Medical Center class: OTHER briefSummary: This study aims to develop a highly sensitive, specific, and cost-effective blood assay for the early detection of esophageal adenocarcinoma and its precursor lesions, using advanced machine learning and state-of-the-art biological analyses. conditions: Esophagus Cancer conditions: Esophageal Cancer Stage conditions: Esophageal Cancer conditions: Esophageal Neoplasms conditions: Esophagus Adenocarcinoma conditions: Esophagus, Barrett conditions: Barrett Esophagus conditions: Barrett Adenocarcinoma conditions: Barrett Epithelium conditions: Barretts Esophagus With Dysplasia conditions: Barrett's Esophagus Without Dysplasia conditions: Barretts Esophagus With High Grade Dysplasia conditions: Barretts Esophagus With Low Grade Dysplasia conditions: Barrett Esophagus, Long-Segment conditions: Barrett's Esophagus With Dysplasia, Unspecified conditions: Barrett's Esophagus With Esophagitis conditions: Gastroesophageal Reflux conditions: Reflux Disease conditions: Esophageal Adenocarcinoma conditions: Esophageal Dysplasia conditions: Esophageal Neoplasms Malignant studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 1000 type: ESTIMATED name: EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia) measure: Sensitivity measure: Specificity measure: Proportion of correct predictions (true positives and true negatives) among the total number of cases (i.e., accuracy) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: City of Hope Medical Center status: RECRUITING city: Duarte state: California zip: 91016 country: United States name: Ajay Goel, PhD role: CONTACT phone: 626-218-3452 email: AJGOEL@COH.ORG name: Ajay Goel, PhD role: PRINCIPAL_INVESTIGATOR name: Alessandro Mannucci, MD role: SUB_INVESTIGATOR lat: 34.13945 lon: -117.97729 hasResults: False
nctId: NCT06381570 id: VICTORY/OZM-138 briefTitle: Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas acronym: VICTORY overallStatus: RECRUITING date: 2024-03-21 date: 2026-03-21 date: 2029-03-21 date: 2024-04-24 date: 2024-04-24 name: Daniel Morgenstern class: OTHER name: The Hospital for Sick Children briefSummary: This is a Pilot, multicenter, open-label study of patients less than or equal to 25 years, with recurrent or progressive LGG harboring a CRAF or BRAF alteration, including BRAF V600 mutations and KIAA1549: BRAF fusions. Patients with BRAF or CRAF alterations will be identified through molecular assays as routinely performed at Clinical Laboratory Improvement Amendments (CLIA) of 1988 or other similarly certified laboratories.
Phase A: A Feasibility (combination dose finding) phase, followed by Phase B: An Efficacy phase. The maximum tolerated dose (MTD)/Recommended Phase 2 Dose (RP2D) of the combination as determined in Phase A would be the dose used in Phase B. The patients on Phase A who were below the MTD/RP2D would be eligible for intra-patient dose escalation to MTD/RP2D subject to criteria outlined later conditions: Low-grade Glioma studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 57 type: ESTIMATED name: Tovorafenib measure: MTD/RP2D measure: Safety and Tolerability measure: Overall response rate measure: Pharmacokinetics (Cmax vinblastine and tovorafenib) measure: Pharmacokinetics (AUC of vinblastine and tovorafenib) measure: Progression free survival measure: Duration of response measure: Clinical Benefit rate sex: ALL minimumAge: 0 Weeks maximumAge: 25 Years stdAges: CHILD stdAges: ADULT facility: The Hospital for Sick Children status: RECRUITING city: Toronto state: Ontario zip: M5G 1X8 country: Canada name: Nirav Thacker role: CONTACT phone: 6137377600 phoneExt: 6525 email: nthacker@cheo.on.ca lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06381557 id: YRPG-PMS-ZYJN-RCT-2022-01 briefTitle: Cancer-related Fatigue in Patients With Breast Cancer Treatment With Zhengyuan Capsules acronym: CRF overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-03-01 date: 2027-03-01 date: 2024-04-24 date: 2024-04-24 name: Qiang Fu class: OTHER name: Yangtze River Pharmaceutical Group Co., Ltd. briefSummary: Traditional Chinese medicine（TCM） has achieved some meaningful results in improving the symptoms and quality of life of cancer patients, but many research results need to be further verified by clinical trials with larger samples and better design.This study aims to investigate effectiveness and safety of Zhengyuan Capsules for cancer-related fatigue in patients with breast cancer. conditions: Cancer-related Fatigue studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 240 type: ESTIMATED name: Zhengyuan Capsules name: Placebo contains 5%-10% Zhengyuan Capsule total mixed powder measure: Fatigue degree with the Brief Fatigue Inventory（BFI） measure: Fatigue degree the Revised Piper Fatigue Scale（PFS⁃R） measure: Fatigue degree with the MD Anderson Symptom Inventory（MDASI） measure: Change of patients' functional status with Karnofsky performance status (KPS) measure: Quality of Life Questionnaire-Breast Cancer Module 23（QLQ-BR23） measure: Adverse reaction rates, including the damage of liver and renal functions that reflected by increased alanine aminotransferase, aspartate aminotransferase and creatinine urea nitrogen respectively sex: FEMALE minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06381544 id: fbu_nurs_elmali_002 briefTitle: The Effect of Aromatherapy Use in Nursing Skills Training overallStatus: COMPLETED date: 2024-02-12 date: 2024-02-19 date: 2024-03-06 date: 2024-04-24 date: 2024-04-24 name: Fenerbahce University class: OTHER briefSummary: Nursing education is an education in which theory and practice are intertwined and requires the development of both cognitive and motor skills of students. The laboratory environment is a bridge between classroom learning and clinical practice. In order for students to transform the target behavior into a skill, it takes place in the laboratory on inanimate models under the supervision of the instructor. It has been assumed that there is a strong relationship between learning and anxiety; while a moderate level of anxiety is necessary for learning, a high level of anxiety causes a decrease in learning.
Many studies have reported that students experience anxiety before their first clinical/practice experience. During skills training, it is observed that students are stressed, their hands are shaking, and they do not feel comfortable, especially before practices involving invasive interventions. This is a factor that makes learning skills training difficult. Therefore, it is important for the student to be comfortable, self-confident, and mentally open to learning during skill training. New applications and different techniques for skill training are important in this sense. It is reported that aromatherapy application has positive effects on reducing anxiety and increasing concentration.
H2: Aromatherapy has a positive effect on students' learning nursing skills. conditions: Nursing Students studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 69 type: ACTUAL name: Aromatherapy application measure: Difference between skill learning of students in the aromatherapy group and the control group measure: Difference between anxiety levels of students in the aromatherapy group and the control group sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fenerbahce University city: Istanbul state: Atasehir zip: 34758 country: Turkey lat: 41.01384 lon: 28.94966 facility: Fenerbahce University city: Ataşehir state: Istanbul zip: 34758 country: Turkey lat: 40.9833 lon: 29.1167 hasResults: False
nctId: NCT06381531 id: 4410 briefTitle: Tracing Brain Tumors Through Deep Time acronym: TRACE overallStatus: NOT_YET_RECRUITING date: 2024-06-10 date: 2027-06-10 date: 2027-06-10 date: 2024-04-24 date: 2024-04-24 name: Tata Memorial Centre class: OTHER name: Indian Statistical Institute, Kolkata briefSummary: Brain tumors involve different age groups with a wide range of tumor types involving different anatomical compartments of the brain. The evolution of the brain in vertebrates, including the most recent homo species (including humans), has occurred through increasing structural complexity in more evolved species. In the retrospective study, we will investigate the location of the tumors and different structural aspects of skull anatomy in patients with brain tumors. The information will be compared with the anatomical evolution of the brain and skull in vertebrates to look for possible associations, which can provide insights into evolutionary biology. conditions: Brain Tumor conditions: Oncology studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 10000 type: ESTIMATED name: Imaging with CT and MRI measure: Age-based density maps of brain tumor location measure: Anthropometric analysis of skulls sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Tata Memorial Hospital city: Mumbai state: Maharashtra zip: 400012 country: India name: Dr Archya Dasgupta, MD role: CONTACT lat: 19.07283 lon: 72.88261 hasResults: False
nctId: NCT06381518 id: Z2023165 briefTitle: Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease acronym: SHUFFLE overallStatus: ENROLLING_BY_INVITATION date: 2024-03-12 date: 2025-05-01 date: 2025-05-01 date: 2024-04-24 date: 2024-04-24 name: Zuyderland Medisch Centrum class: OTHER briefSummary: The aim of this study is to evaluate the IFX exposure (AUC), effectiveness, presence of ADAbs and treatment burden before and after switching from IV to SC IFX maintenance treatment in a real-world cohort of IBD patients with quiescent disease on IFX monotherapy and combination therapy of IFX and an immunomodulator.
The study is subdivided into two phases: the IV IFX treatment phase before switching and the SC CT-P13 treatment phase after the switch. After enrolment, the subject receives a final dose of IV IFX according to their own maintenance schedule. Primary endpoints are the Area under the concentration-time curve (AUC) at steady state (1) before and after the switch to SC CT-P13 and (2) with or without concomitant immunomodulator during SC therapy. AUCs will be estimated using pharmacokinetic modelling in MwPharm. Besides IFX trough level, treatment related time expenditure, quality-of-life and patient satisfaction will be assessed before and after the switch. conditions: IBD conditions: Infliximab conditions: Crohn Disease conditions: Ulcerative Colitis studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: This is a prospective, single centre, open-label cohort study, conducted in Zuyderland Medical Centre in which adult IBD patients in remission on stable IV IFX therapy are switched to SC CT-P13 and is designed to compare the pharmacokinetics of SC CT-P13 to IV IFX and relate this to the pharmacodynamics. primaryPurpose: TREATMENT masking: NONE count: 36 type: ESTIMATED name: Switch to SC CT-P13. measure: Area under the curve (AUC) at steady state measure: Quality of life score measure: Patient satisfaction measure: Time expenditure sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zuyderland Medical Centre city: Sittard country: Netherlands lat: 50.99833 lon: 5.86944 hasResults: False